This study was a randomized, controled, multicenter, phase II clinical study evaluating the
efficacy and safety of fruquintinib as a maintenance therapy following first-line treatment
for metastatic colorectal cancer. This study will include the patients with confirmed
unresectable metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer
who achieved stable disease (SD) or partial response (PR) or complete response (CR) via
palliative first-line treatment. It's expected to include 110 patients and they will be
randomly stratified at 2:1 into fruquintinib group and observation group based on whether
bevacizumab is used and the primary tumor site, using the Interactive Network Response System
(IWRS). The random No. corresponds to the respective patient. The enrollment time is expected
to be 18 months, followed up for 24 months.
Colorectal Cancer, Colon cancer; rectal cancer, Colon Cancer Screening
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.